Trial Profile
Therapeutic Efficacy and Safety of Mirabegron , a β3-Adrenoceptor Agonist, Treatment on Patients With Overactive Bladder Syndrome in Taiwan - Predictive Factors for the First Line Use and the Dose Effectiveness Relationship
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Mirabegron (Primary) ; Solifenacin
- Indications Overactive bladder
- Focus Therapeutic Use
- 02 Mar 2017 New trial record